NIH pre-clinical screening program: overview and current status

被引：27

作者：

Izzo, A

Brandt, L

Lasco, T

Kipnis, AP

Orme, I

机构：

[1] Colorado State Univ, Immunol & Pathol Labs, Dept Microbiol, Ft Collins, CO 80523 USA

[2] Colorado State Univ, Mycobacterial Res Lab, Dept Microbiol, Ft Collins, CO 80523 USA

来源：

TUBERCULOSIS | 2005年 / 85卷 / 1-2期

关键词：

tuberculosis; vaccine; pre-clinical;

D O I：

10.1016/j.tube.2004.09.008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The increase in the number of cases of Mycobocterium tuberculosis around the world has lead to a greater need for a more efficacious vaccine than the currently used M. bovis BCG. Despite the relative success of this attenuated vaccine there are multiple examples where alternative strategies are desperately needed. In 1996, the National Institutes of Health published a request calling for applications to test newly developed vaccines against tuberculosis. The current screening program at Colorado State University has tested a wide range of novel vaccine candidates. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：25 / 28

页数：4

共 3 条

[1] ESAT-6 subunit vaccination against Mycobacterium tuberculosis [J].